{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INB\",,,,,undefined,":{"symbol":"INB","market":"US","secType":"STK","nameCN":"Cohen & Steers Global Income Builder Inc","latestPrice":9.15,"timestamp":1576875600000,"preClose":9.15,"halted":4,"volume":0,"delay":0,"floatShares":0,"shares":23142000,"eps":0.3606,"marketStatus":"Delisted","change":0,"latestTime":"12-20 16:00:00 EST","open":9.15,"high":9.15,"low":9.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.3606,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747641600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":9.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INB\",,,,,undefined,":{"symbol":"INB","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":23142000,"dividePrice":0,"high":9.15,"amplitude":0,"preClose":9.15,"low":9.15,"week52Low":7.1599,"pbRate":"--","week52High":9.3,"institutionHeld":0,"latestPrice":9.15,"eps":0.3606,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.3606,"open":9.15},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/INB\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRS","BK4006","BK4539","IE0031619046.USD","IE00B66KJ199.SGD","BK4211","CR","INAB","INB","BK4097","BK4195","IE00B7SZL793.SGD","OS","BK4139","LU2065731478.USD","IE00B19Z4B17.USD","BK4161","PFS"],"gpt_icon":0},{"id":"2512484426","title":"INAB: Continued Survival in INB-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512484426","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512484426?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:11","pubTimestamp":1739963460,"startTime":"0","endTime":"0","summary":"IN8bio, Inc  updates survival data for its INB-100 trial in a February 11thpress release in preparation for presentation of data at the Transplantation & Cellular Therapy  Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival  and overall survival . Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.The results are remarkable as real-world survival rates for AML patients following hematopoietic stem cell transplantation  are lower. For example, the Center for International Blood and Marrow Transplant Research  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-continued-survival-inb-100-111100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","IE00B66KJ199.SGD","HSCT","IE0031619046.USD","BK4161","INAB","BK4195","BK4006","IE00B19Z4B17.USD","BK4097","INB","BK4139","LU2065731478.USD","IE00B7SZL793.SGD","PFS","BK4539","CR","CRS","BK4211"],"gpt_icon":0},{"id":"2512844952","title":"Backing Winners: Core Energy’s strategy to mirror winning model of Latin Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2512844952","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512844952?lang=en_us&edition=fundamental","pubTime":"2025-02-17 04:40","pubTimestamp":1739738420,"startTime":"0","endTime":"0","summary":"Backing Winners isStockhead’s regular recap of executives with a solid track record looking to replicate the success of their previous roles.Today we hear from Anthony Greenaway, executive director at Core Energy Minerals and previous VP operations at Latin Resources.Can you tell us about some of the key learnings you’ve taken away from your time at Latin, in particular the major factors that led to its success and eventual takeover?I’ve been a non-executive director of Core Energy Mineralsfor a number of years and before that, I was exploration manager for Oar Resources – the company before it transitioned into Core – so I’ve been involved with this group for almost five years.Chris Gale and I have very good government relations in Brazil through our work with Latin and while we know Brazil very well, it has been a closed shop for uranium for many years in that all the uranium deposits have been controlled by the government.That has all changed, the Brazilian government has recognised","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/backing-winners-one-640x359.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/backing-winners-one-640x359.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/backing-winners-core-energys-strategy-to-mirror-winning-model-of-latin-resources/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["INB"],"gpt_icon":0},{"id":"2511937176","title":"IN8bio presented Phase 1 data on INB-100 at 2025 TCT","url":"https://stock-news.laohu8.com/highlight/detail?id=2511937176","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511937176?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:05","pubTimestamp":1739541953,"startTime":"0","endTime":"0","summary":"IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, TCT, Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/in8bio-presented-phase-1-data-on-inb-100-at-2025-tct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/in8bio-presented-phase-1-data-on-inb-100-at-2025-tct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INAB","INB","BK4539","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-12-03","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-12-04","currency":"USD","type":"dividend","dateTimestamp":1575349200000},{"market":"US","date":"2019-11-12","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-11-13","currency":"USD","type":"dividend","dateTimestamp":1573534800000},{"market":"US","date":"2019-10-15","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-10-16","currency":"USD","type":"dividend","dateTimestamp":1571112000000},{"market":"US","date":"2019-09-17","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-09-18","currency":"USD","type":"dividend","dateTimestamp":1568692800000},{"market":"US","date":"2019-08-20","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-08-21","currency":"USD","type":"dividend","dateTimestamp":1566273600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INB\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-03-21","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INB\",market:\"US\",delay:false,,,undefined,":{}}}